JP6466456B2 - 抗がん剤としての三環式化合物 - Google Patents

抗がん剤としての三環式化合物 Download PDF

Info

Publication number
JP6466456B2
JP6466456B2 JP2016542692A JP2016542692A JP6466456B2 JP 6466456 B2 JP6466456 B2 JP 6466456B2 JP 2016542692 A JP2016542692 A JP 2016542692A JP 2016542692 A JP2016542692 A JP 2016542692A JP 6466456 B2 JP6466456 B2 JP 6466456B2
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
methyl
substituted
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016542692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505762A (ja
JP2017505762A5 (enExample
Inventor
デレク・ジェイ・ノリス
ジョージ・ブイ・デルッカ
アシュビニクマール・ブイ・ガバイ
クロード・ア・ケスネル
パトリス・ジル
ダニエル・オマリー
ウェイン・バッカロ
リー・フランシス・ワイ
ミッケル・ブイ・デベネデット
アンドリュー・ピー・デグナン
ファン・ハイチュエン
マシュー・ディ・ヒル
ホン・ホアン
ウィリアム・ディ・シュミッツ
ジョン・イー・スターレット・ジュニア
ウェン−チン・ハン
ジョン・エス・トカルスキー
スニル・クマール・マンダル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2017505762A publication Critical patent/JP2017505762A/ja
Publication of JP2017505762A5 publication Critical patent/JP2017505762A5/ja
Application granted granted Critical
Publication of JP6466456B2 publication Critical patent/JP6466456B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
JP2016542692A 2013-12-24 2014-12-23 抗がん剤としての三環式化合物 Active JP6466456B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920500P 2013-12-24 2013-12-24
US61/920,500 2013-12-24
PCT/US2014/072031 WO2015100282A1 (en) 2013-12-24 2014-12-23 Tricyclic compounds as anticancer agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019002078A Division JP6675501B2 (ja) 2013-12-24 2019-01-09 抗がん剤としての三環式化合物

Publications (3)

Publication Number Publication Date
JP2017505762A JP2017505762A (ja) 2017-02-23
JP2017505762A5 JP2017505762A5 (enExample) 2017-12-21
JP6466456B2 true JP6466456B2 (ja) 2019-02-06

Family

ID=52293305

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016542692A Active JP6466456B2 (ja) 2013-12-24 2014-12-23 抗がん剤としての三環式化合物
JP2019002078A Active JP6675501B2 (ja) 2013-12-24 2019-01-09 抗がん剤としての三環式化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019002078A Active JP6675501B2 (ja) 2013-12-24 2019-01-09 抗がん剤としての三環式化合物

Country Status (34)

Country Link
US (1) US20160318928A1 (enExample)
EP (2) EP3466949B1 (enExample)
JP (2) JP6466456B2 (enExample)
KR (1) KR102457145B1 (enExample)
CN (2) CN106029663B (enExample)
AR (2) AR099379A1 (enExample)
AU (1) AU2014369982B2 (enExample)
BR (1) BR112016013744B1 (enExample)
CA (1) CA2934953C (enExample)
CL (1) CL2016001629A1 (enExample)
CY (2) CY1121076T1 (enExample)
DK (2) DK3466949T3 (enExample)
EA (2) EA032469B1 (enExample)
ES (2) ES2857848T3 (enExample)
HR (2) HRP20181849T1 (enExample)
HU (2) HUE054183T2 (enExample)
IL (1) IL246359B (enExample)
LT (2) LT3466949T (enExample)
MA (1) MA39211B1 (enExample)
MX (1) MX369491B (enExample)
MY (1) MY176489A (enExample)
NZ (1) NZ722326A (enExample)
PE (1) PE20160844A1 (enExample)
PH (1) PH12016500953A1 (enExample)
PL (2) PL3466949T3 (enExample)
PT (2) PT3087071T (enExample)
RS (2) RS58014B1 (enExample)
SG (1) SG11201605097SA (enExample)
SI (2) SI3466949T1 (enExample)
SM (2) SMT201800643T1 (enExample)
TN (1) TN2016000238A1 (enExample)
TW (2) TWI736517B (enExample)
UY (1) UY35916A (enExample)
WO (1) WO2015100282A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053454B2 (en) 2013-02-27 2018-08-21 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
SI3466949T1 (sl) * 2013-12-24 2021-03-31 Bristol-Myers Squibb Company Triciklična spojina kot sredstvo proti raku
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
CA2940554A1 (en) * 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
US10174024B2 (en) 2015-05-12 2019-01-08 Bristol-Myers Squibb Company 5H-pyrido[3,2-B]indole compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
JP7032311B2 (ja) 2015-07-16 2022-03-08 バイオエクセル セラピューティクス，インコーポレイテッド 免疫調節を使用してがんを処置するための新規手法
CA2999523A1 (en) * 2015-10-02 2017-04-06 Dana-Farber Cancer Institute, Inc. Combination therapy of bromodomain inhibitors and checkpoint blockade
EP3406612B1 (en) 2016-01-20 2021-07-21 Ningbo Wenda Pharma Technology Ltd. Carboline derivative serving as bromodomain inhibitor
WO2017124934A1 (zh) * 2016-01-20 2017-07-27 宁波文达医药科技有限公司 作为布罗莫区结构域抑制剂的含膦咔啉衍生物
WO2017133681A1 (zh) * 2016-02-05 2017-08-10 正大天晴药业集团股份有限公司 溴区结构域蛋白抑制剂的三环类化合物及其制备、药物组合物和用途
AU2017228329B2 (en) 2016-03-01 2021-03-11 Corcept Therapeutics, Inc. The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
US10150754B2 (en) * 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US20190284192A1 (en) 2016-11-10 2019-09-19 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof
CN109824693B (zh) * 2017-04-18 2020-12-08 四川大学 Brd4抑制剂及其在肿瘤治疗药物中的应用
WO2019080941A1 (en) * 2017-10-27 2019-05-02 Jacobio-Beta Pharmaceuticals Co., Ltd. NEW TRICYCLIC COMPOUNDS
EA202190103A1 (ru) 2018-06-25 2021-03-29 Джакобио Фармасьютикалс Ко., Лтд. Трициклические соединения
CN108840868B (zh) * 2018-08-01 2019-10-18 上海山的实业有限公司 具有抗肿瘤活性的吲哚并吡啶酮类化合物的制备方法及应用
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN113544129B (zh) * 2019-04-04 2024-07-23 上海华汇拓医药科技有限公司 三环类化合物制备方法及其在医药领域的应用
CN110003204B (zh) * 2019-04-30 2020-08-11 上海勋和医药科技有限公司 一种bet蛋白抑制剂、其制备方法及用途
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
JP7642552B2 (ja) 2019-09-30 2025-03-10 協和キリン株式会社 Ｂｅｔ分解剤
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
WO2022156757A1 (en) * 2021-01-22 2022-07-28 Jingrui Biopharma Co., Ltd. Tricyclic compounds as anticancer agents
WO2022182857A1 (en) * 2021-02-25 2022-09-01 Impact Biomedicines, Inc. Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
IL308270A (en) * 2021-05-06 2024-01-01 Raziel Therapeutics Ltd Consequence of crystalline carbazole
WO2024099441A1 (en) * 2022-11-11 2024-05-16 Jingrui Biopharma (Shandong) Co., Ltd. Bromodomain and extra-terminal (bet) protein degrader

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014080A1 (en) * 1992-01-15 1993-07-22 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
CA2542682A1 (en) 2003-10-18 2005-05-06 Bayer Healthcare Ag 5-substituted 2-(phenylmethyl) thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases
EP1686949A2 (en) * 2003-11-24 2006-08-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
WO2006122150A1 (en) 2005-05-10 2006-11-16 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
HRP20080053A2 (hr) 2005-07-01 2009-08-31 Medarex Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1)
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
ES2444574T3 (es) 2006-09-19 2014-02-25 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
CN101801413A (zh) 2007-07-12 2010-08-11 托勒克斯股份有限公司 采用gitr结合分子的联合疗法
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
FR2927330B1 (fr) 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CA3120172A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2370407B1 (en) * 2008-12-19 2014-06-18 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
PL3023438T3 (pl) 2009-09-03 2020-07-27 Merck Sharp & Dohme Corp. Przeciwciała anty-gitr
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
RS58693B1 (sr) 2009-12-10 2019-06-28 Hoffmann La Roche Antitela koja poželjno vezuju ekstracelularni domen 4 humanog csf1r, i njihova primena
AU2011219758A1 (en) 2010-02-26 2012-08-16 Boehringer Ingelheim International Gmbh 4 - [cycloalkyloxy (hetero) arylamino] thieno [2, 3 - d] pyrimidines having Mnkl/ Mnk2 inhibiting activity for pharmaceutical compositions
PT2542256T (pt) 2010-03-04 2019-09-05 Macrogenics Inc Anticorpos reativos com b7-h3, fragmentos imunologicamente ativos dos mesmos e sua utilização
CN102918060B (zh) 2010-03-05 2016-04-06 霍夫曼-拉罗奇有限公司 抗人csf-1r抗体及其用途
BR112012022046A2 (pt) 2010-03-05 2017-02-14 F Hoffamann-La Roche Ag ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
TWI503323B (zh) * 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
SG10201911345WA (en) 2010-05-04 2020-01-30 Five Prime Therapeutics Inc Antibodies that bind csf1r
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
RU2551963C2 (ru) 2010-09-09 2015-06-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1вв
AR084312A1 (es) * 2010-12-16 2013-05-08 Genentech Inc Compuestos triciclicos inhibidores de la pi3k y composiciones farmaceuticas
US8580399B2 (en) 2011-04-08 2013-11-12 Universal Display Corporation Substituted oligoazacarbazoles for light emitting diodes
NO2694640T3 (enExample) 2011-04-15 2018-03-17
EP3403672A1 (en) 2011-04-20 2018-11-21 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
KR20140068883A (ko) * 2011-09-28 2014-06-09 이데미쓰 고산 가부시키가이샤 유기 전계 발광 소자용 재료 및 이를 사용한 유기 전계 발광 소자
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
JP6242804B2 (ja) 2011-12-15 2017-12-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
CA2861122A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AU2012374617B2 (en) 2012-05-11 2015-09-17 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN104684582A (zh) 2012-08-31 2015-06-03 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
US10053454B2 (en) * 2013-02-27 2018-08-21 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
JP6401773B2 (ja) * 2013-03-11 2018-10-10 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法
SI3466949T1 (sl) * 2013-12-24 2021-03-31 Bristol-Myers Squibb Company Triciklična spojina kot sredstvo proti raku

Also Published As

Publication number Publication date
KR20160095168A (ko) 2016-08-10
AR099379A1 (es) 2016-07-20
RS61479B1 (sr) 2021-03-31
BR112016013744A2 (enExample) 2017-10-03
US20160318928A1 (en) 2016-11-03
LT3466949T (lt) 2021-03-25
SI3087071T1 (sl) 2018-11-30
EP3466949A1 (en) 2019-04-10
HRP20210212T1 (hr) 2021-07-09
KR102457145B1 (ko) 2022-10-19
LT3087071T (lt) 2018-11-12
MA39211A1 (fr) 2018-08-31
UY35916A (es) 2015-06-30
JP2017505762A (ja) 2017-02-23
AU2014369982A1 (en) 2016-08-04
HRP20181849T1 (hr) 2018-12-28
WO2015100282A1 (en) 2015-07-02
PL3466949T3 (pl) 2021-05-31
SI3466949T1 (sl) 2021-03-31
PH12016500953A1 (en) 2016-06-27
SMT201800643T1 (it) 2019-01-11
TN2016000238A1 (en) 2017-10-06
IL246359A0 (en) 2016-08-31
CA2934953A1 (en) 2015-07-02
ES2857848T3 (es) 2021-09-29
HUE054183T2 (hu) 2021-08-30
RS58014B1 (sr) 2019-02-28
PE20160844A1 (es) 2016-09-03
CY1124061T1 (el) 2022-05-27
AU2014369982B2 (en) 2019-04-18
MY176489A (en) 2020-08-12
MX369491B (es) 2019-11-11
DK3087071T3 (da) 2019-01-02
CN108558871A (zh) 2018-09-21
EP3087071B1 (en) 2018-09-05
EA201990240A1 (ru) 2019-06-28
EP3466949B1 (en) 2020-12-23
NZ722326A (en) 2019-09-27
ES2698998T3 (es) 2019-02-06
MX2016007928A (es) 2016-08-03
EP3087071A1 (en) 2016-11-02
MA39211B1 (fr) 2019-01-31
HUE041719T2 (hu) 2019-05-28
CN106029663B (zh) 2018-06-01
CN106029663A (zh) 2016-10-12
PT3087071T (pt) 2018-11-29
SG11201605097SA (en) 2016-07-28
DK3466949T3 (da) 2021-03-15
EA032469B1 (ru) 2019-05-31
AR123996A2 (es) 2023-02-01
CY1121076T1 (el) 2019-12-11
TWI736517B (zh) 2021-08-21
TW202028203A (zh) 2020-08-01
BR112016013744B1 (pt) 2022-08-30
HRP20210212T8 (hr) 2021-08-20
IL246359B (en) 2020-04-30
JP6675501B2 (ja) 2020-04-01
TWI726544B (zh) 2021-05-01
PL3087071T3 (pl) 2019-03-29
CN108558871B (zh) 2022-02-18
CL2016001629A1 (es) 2017-02-17
CA2934953C (en) 2022-09-20
TW201609725A (zh) 2016-03-16
JP2019070014A (ja) 2019-05-09
EA201691070A1 (ru) 2016-11-30
PT3466949T (pt) 2021-02-25
SMT202100165T1 (it) 2021-05-07

Similar Documents

Publication Publication Date Title
JP6675501B2 (ja) 抗がん剤としての三環式化合物
US10112941B2 (en) Tricyclic compounds as anticancer agents
US9725449B2 (en) Tricyclic compounds as anticancer agents
KR20230143632A (ko) Irak 분해제 및 이의 용도
US10174024B2 (en) 5H-pyrido[3,2-B]indole compounds as anticancer agents
CN108026105A (zh) TGFβ受体拮抗剂
HK1225023A1 (en) Tricyclic compounds as anticancer agents
HK1225023B (en) Tricyclic compounds as anticancer agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171113

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181211

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190109

R150 Certificate of patent or registration of utility model

Ref document number: 6466456

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250